CRO giant Parexel has seen its chief financial officer and senior vice president Ingo Bank resign from the company over the weekend, according to a SEC filing.
Parexel, which is set to post its Q4/FY financial results in just over two weeks’ time (August 3), said Bank had left “in order to take a senior leadership role in another company,” without specifying where.
The Waltham, MA-based CRO said it intends quickly start looking for a permanent CFO. Bank will however continue to be an employee until mid-August, in order to help “assist in the transition of his position,” the SEC filing said.
Emma Reeve has been named interim CFO. She has been the company’s corporate VP since 2014.
Parexel said that Reeve has more than 20 years of experience in life sciences financial management, having worked as head of finance and administration for Novartis ($NVS), and has also served as biotech CFO before, notably at Inotek Pharmaceuticals.
Last October, Parexel narrowed its outlook for fiscal 2016, reducing its revenue target by about 2% at midpoint to around $2.14 billion amid sliding profits.
The CRO has also been in the process of shedding around 850 jobs during the past year, with the goal of saving between $20 million and $30 million a year starting from 2016.
By Ben Adams
Source: Fierce Biotech
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
